Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (NCT05653349)
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in adult participants with primary ITP.
Who can join: Review the eligibility criteria below.
Location: Yuma Regional Medical Center — Yuma, Arizona
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (111 Sites)
Showing the first 25 of 111 sites.
- Yuma Regional Medical Center — Yuma, Arizona
- Community Cancer Institute — Clovis, California
- Compassionate Care Res Group Inc — Fountain Valley, California
- University of Colorado Anschutz — Aurora, Colorado
- DH Cancer Research Center LLC — Margate, Florida
- Uni of Chi Medi Ctr Hema and Onco — Chicago, Illinois
- Parkview Research Center — Fort Wayne, Indiana
- Oncology Care Associates — Bethesda, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Med Center — Boston, Massachusetts
- Michigan Center of Medical Research — Farmington Hills, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- Metro Minnesota CCOP — Saint Louis Park, Minnesota
- St Vincent Frontier Cancer Center — Billings, Montana
- Optum Health — Lake Success, New York
- Hematology Oncology Association of Rockland — Nyack, New York
- STAT Research Inc — Dayton, Ohio
- Rhode Island Hospital — Providence, Rhode Island
- Mays Cancer Ctr Uthsa Mdacc — San Antonio, Texas
- Community Cancer Trials of Utah — Ogden, Utah
- Novartis Investigative Site — CABA, Buenos Aires
- Novartis Investigative Site — CABA, Buenos Aires
- Novartis Investigative Site — San Miguel Tucuman, Tucumán Province
- Novartis Investigative Site — Caba,
- Novartis Investigative Site — Córdoba,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Immune Thrombocytopenia (ITP)
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — Boston, Massachusetts
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) — Fayetteville, Arkansas
- A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia — Phoenix, Arizona
Explore by condition: All Primary Immune Thrombocytopenia (ITP) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.